Histopathology News and Research

RSS

Report alerts clinicians, public about catastrophic dangers of contaminated epidural injections

Investigators from the Centers for Disease Control and Prevention describe pathologic findings from 40 case reports of fungal infection in patients who had been given contaminated epidural, paraspinal, or intra-articular (into joints) steroid injections and correlate these findings with clinical and laboratory data.

26 Jun 2013

Six abstracts and clinical data on Cook Medical products to be presented at DDW 2013

At this week's Digestive Disease Week, the world's largest gathering of physicians and researchers in the gastroenterology field, six abstracts and other clinical data will be presented on Cook Medical products.

18 May 2013

Clinical data on Cook Medical products to be presented at Digestive Disease Week®

At this week’s Digestive Disease Week (DDW), the world’s largest gathering of physicians and researchers in the gastroenterology field, six abstracts and other clinical data will be presented on Cook Medical products. Cook’s EchoTip® ProCore™ High Definition Ultrasound Biopsy needles are featured in many of these presentations.

17 May 2013

Previstage GCC Colorectal Cancer Staging Test study to be presented at 2013 ASCO Annual Meeting

DiagnoCure Inc., today announced that results from a large validation study of the PrevistageTM GCC Colorectal Cancer Staging Test have been selected for presentation at the 2013 American Society of Clinical Oncology Annual Meeting, taking place in Chicago, Illinois from May 31 to June 4, 2013.

16 May 2013

Researchers improve NanoVelcro device to better grab cancer cells as blood passes by them

Researchers at UCLA report that they have refined a method they previously developed for capturing and analyzing cancer cells that break away from patients' tumors and circulate in the blood. With the improvements to their device, which uses a Velcro-like nanoscale technology, they can now detect and isolate single cancer cells from patient blood samples for analysis.

26 Feb 2013

Immune Pharmaceuticals commences Phase II study with bertilimumab to treat ulcerative colitis

Immune Pharmaceuticals Ltd., a privately held Israeli company, and EpiCept Corporation announced today that Immune is initiating, following authorization from Israeli health authorities, a Phase II double-blind placebo controlled study with its lead drug, bertilimumab, in patients with moderate-to-severe ulcerative colitis.

21 Feb 2013

Human papillomavirus an etiologic factor in 6% of OCSCC cases

High-risk human papillomavirus is an etiologic factor in approximately 6% of cases of oral cavity squamous cell carcinoma, according to epidemiologic research.

14 Jan 2013

Infrared therapy could help prevent anal cancer in HIV-positive population

Infrared coagulopathy treatment of a potential precursor of anal cancer is effective and warrants further study as a way to reduce anal cancer incidence and mortality among HIV-infected people, report researchers.

30 Nov 2012

Tissue test detects oral cancer risk

A molecular diagnostic scoring system based on patients’ FOXM1-associated gene messenger RNA expression levels is able to quantitatively diagnose and stratify oral carcinoma and its aggressiveness, show UK and Norwegian study results.

11 Oct 2012

NIH awards $2.1M grant to study possible ways to fight cancer

A professor with the University of Houston Cullen College of Engineering has won a $2.1 million grant to study the best ways to modify human immune cells to fight against cancer.

6 Oct 2012

New gene test can detect pre-cancerous cells in patients with mouth lesions

Researchers from Queen Mary, University of London have developed a new gene test that can detect pre-cancerous cells in patients with benign-looking mouth lesions. The test could potentially allow at-risk patients to receive earlier treatment, significantly improving their chance of survival.

5 Oct 2012

NanoBio to present data from preclinical studies at 8th Annual International RSV Symposium

NanoBio Corporation announced today it will present data from three preclinical studies at the 8th Annual International Respiratory Syncytial Virus (RSV) Symposium taking place from Sept. 27-30 in Santa Fe, N.M.

25 Sep 2012

NanoViricides’ oral FluCide dramatically improves survival in animals with H3N2 influenza A

NanoViricides, Inc. reported today that its oral FluCide drug candidates demonstrated dramatically improved survival in animals administered a lethal dose of the H3N2 influenza A virus.

24 Sep 2012

GE Healthcare announces final results from [18F]flutemetamol phase 3 study on AD

GE Healthcare today announced the final results from a phase 3 study of the investigational PET amyloid imaging agent, [18F]flutemetamol in terminally ill patients who had agreed to undergo postmortem brain autopsy.

18 Jul 2012

FDA acknowledges receipt of resubmission of Human Genome Sciences’ raxibacumab BLA

Human Genome Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmission of the Biologics License Application (BLA) for raxibacumab, a treatment for inhalational anthrax, and has established December 15, 2012 as the Prescription Drug User Fee Act (PDUFA) action date.

10 Jul 2012

Afirma gene expression test can reduce unnecessary thyroid cancer surgeries

Veracyte, Inc., a molecular diagnostics company that is pioneering the emerging field of molecular cytology, today announced results from a large, prospective, multicenter study, which demonstrated the potential for the Afirma® Gene Expression Classifier, a gene expression test, to reduce the large number of unnecessary surgeries in thyroid cancer diagnosis by more than half.

25 Jun 2012

MDxHealth announces availability of ConfirmMDx for Prostate Cancer test

MDxHealth SA, a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced it has presented data demonstrating that its epigenetic ConfirmMDx for Prostate Cancer test can aid urologists in identifying patients who may avoid a repeat prostate biopsy.

23 May 2012

SPECT/CT can change clinical management of thyroid cancer

The use of single positron emission computed tomography (SPECT)/computed tomography (CT) has been reported to change clinical management in a significant number of thyroid cancer patients according to research presented in the May issue of The Journal of Nuclear Medicine.

4 May 2012

Alnylam first quarter revenues decrease to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2012, and company highlights.